In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genocea Aims To Take The T-Cell Century By The Horns

Executive Summary

Although cancer grabs the spotlight for harnessing the immune system against tumors, other therapeutic areas and modalities are being developed in the shadows. Genocea Biosciences thinks it has a surefire way to identify novel antigens for T-cell vaccines. It hopes to shake up large infectious disease markets, and more.

You may also be interested in...



Global Vaccines: A Shot Of Growth For GSK And Pfizer?

Recent M&A activity in the vaccine industry has narrowed the pool of players. For companies that remain, the opportunity to reshape their positions in the global market comes with an even greater responsibility to contribute meaningfully to continued advances in global public health.

Vaccine Funding And Access Key To Pharma Success In Developing World

Vaccine consultant Jacqueline Keith in an interview described promising advances but also challenges to the funding, development, and delivery of vaccines to the neediest populations. The role of public/private partnerships at each stage of the vaccine value chain is critical to assuring win-win outcomes.

GSK Prepares For Malaria Vaccine Roll-Out In Africa By 2015

“While we have seen some decline in vaccine efficacy over time, the sheer number of children affected by malaria means that the number of cases of the disease the vaccine can help prevent is impressive,” GSK CEO Witty says.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS140995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel